Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus

Rina Mina, Emily Von Scheven, Stacy P. Ardoin, B. Anne Eberhard, Marilynn Punaro, Norman Ilowite, Joyce Hsu, Marisa Klein-Gitelman, L. Nandini Moorthy, Eyal Muscal, Suhas M. Radhakrishna, Linda Wagner-Weiner, Matthew Adams, Peter Blier, Lenore Buckley, Elizabeth Chalom, Gaëlle Chédeville, Andrew Eichenfield, Natalya Fish, Michael HenricksonAimee O. Hersh, Roger Hollister, Olcay Jones, Lawrence Jung, Deborah Levy, Jorge Lopez-Benitez, Deborah McCurdy, Paivi M. Miettunen, Ana I. Quintero-Del Rio, Deborah Rothman, Ornella Rullo, Natasha Ruth, Laura E. Schanberg, Earl Silverman, Nora G. Singer, Jennifer Soep, Reema Syed, Larry B. Vogler, Ali Yalcindag, Cagri Yildirim-Toruner, Carol A. Wallace, Hermine I. Brunner

Research output: Contribution to journalArticlepeer-review

97 Scopus citations

Abstract

Objective. To formulate consensus treatment plans (CTPs) for induction therapy of newly diagnosed proliferative lupus nephritis (LN) in juvenile systemic lupus erythematosus (SLE). Methods. A structured consensus formation process was employed by the members of the Childhood Arthritis and Rheumatology Research Alliance after considering the existing medical evidence and current treatment approaches. Results. After an initial Delphi survey (response rate = 70%), a 2-day consensus conference, and 2 followup Delphi surveys (response rates = 63-79%), consensus was achieved for a limited set of CTPs addressing the induction therapy of proliferative LN. These CTPs were developed for prototypical patients defined by eligibility characteristics, and included immunosuppressive therapy with either mycophenolic acid orally twice per day, or intravenous cyclophosphamide once per month at standardized dosages for 6 months. Additionally, the CTPs describe 3 options for standardized use of glucocorticoids, including a primarily oral, a mixed oral/intravenous, and a primarily intravenous regimen. There was consensus on measures of effectiveness and safety of the CTPs. The CTPs were well accepted by the pediatric rheumatology providers treating children with LN, and up to 300 children per year in North America are expected to be candidates for the treatment with the CTPs. Conclusion. CTPs for induction therapy of proliferative LN in juvenile SLE based on the available scientific evidence and pediatric rheumatology group experience have been developed. Consistent use of the CTPs may improve the prognosis of proliferative LN, and support the conduct of comparative effectiveness studies aimed at optimizing therapeutic strategies for proliferative LN in juvenile SLE.

Original languageEnglish
Pages (from-to)375-383
Number of pages9
JournalArthritis Care and Research
Volume64
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint Dive into the research topics of 'Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus'. Together they form a unique fingerprint.

Cite this